市场调查报告书
商品编码
1403564
自动细胞计数全球市场规模、份额、产业趋势分析报告:2023-2030 年按产品、应用、最终用途、地区分類的展望与预测Global Automated Cell Counting Market Size, Share & Industry Trends Analysis Report By Product, By Application (Cell Line development, Blood Analysis, Stem Cell Research, and Others), By End-use, By Regional Outlook and Forecast, 2023 - 2030 |
自动细胞计数市场规模预计到 2030 年将达到 86 亿美元,预测期内复合年增长率为 12.2%。
根据 KBV 基数矩阵中的分析,F. Hoffmann-La Roche Ltd. 是市场上的领导者。 2021 年12 月,F. Hoffmann-La Roche Ltd. 宣布推出三款用于乳癌影像分析的全新自动化数位病理演算法:uPath Ki-67 (30-9)、uPath PR (1E2) 和uPath ER (SP1 )。该演算法透过在病理学家评估之前自动预先计算玻片影像来促进整个玻片分析工作流程,这有助于病理学家量化乳癌标记。 Thermo Fisher Scientific、Abbott Laboratories 和 Danaher Corporation 等公司是该市场的主要创新者。
COVID-19 影响分析
在大流行期间,研究工作和资源主要用于了解 SARS-CoV-2 病毒、开发诊断测试和开发疫苗。研究重点的这种暂时转变导致一些非新冠病毒相关研究领域的放缓,例如其他领域的自动细胞计数应用。这场流行病扰乱了全球供应链,影响了机械细胞计数设备和相关耗材的生产、分销和可用性。製造延误、出货限制和物流挑战暂时影响了市场成长。因此,COVID-19大流行对市场产生了温和的影响。
市场成长要素
增加政府研发支出
增加政府对细胞研究的资助对于推进细胞生物学、再生医学和相关领域的科学发现、创新和治疗方法开发至关重要。增加的资金将使科学家更了解不同细胞类型的细胞机制、讯号途径和行为。这些基础知识为开发慢性病的标靶治疗和介入措施提供了基础。探索干细胞在再生医学、组织工程和疾病建模中的潜力为新的治疗方法和器官再生打开了大门。因此,增加政府对研发的资助正在推动市场成长。
对细胞食品的需求不断增长
细胞农业领域的不断扩大,包括以细胞为基础的牲畜、乳製品、鸡蛋和其他产品的生产,为自动细胞计数设备带来了新的应用。细胞生长和培养是製造过程的重要组成部分,需要密切监控。为食品生物製造设施开发符合良好生产规范 (GMP) 的自动计数解决方案的公司可以在这一利基市场中获得价值。投资细胞农业公司并与之合作可以提供长期扩张机会。因此,细胞食品的上升趋势正在推动市场成长。
市场抑制因素
需要专门的操作人员和培训
先进的自动化细胞计数器需要熟练的员工和技术知识才能有效地操作和维护。许多实验室由于预算和资源限製而被迫提供专门培训。一个限制因素是缺乏合格的人力资源来充分发挥系统的潜力。护理学校和医学院等医疗保健教育计画能力不足,限制了进入该领域的合格专业人员的数量。因此,缺乏训练有素的熟练劳动力阻碍了市场的成长。
产品展望
按产品划分,市场分为电器和消耗品/配件。 2022 年,消耗品和配件领域在市场中占有最高的收益占有率。随着流式细胞仪、基于影像的细胞计数器和血液分析仪等自动细胞计数设备的采用不断增加,对与这些设备相关的耗材和配件的需求也在增加。该市场对耗材和配件的需求不断增长,与细胞分析技术的不断扩大的应用以及标准化和品管的需要密切相关。
设备展望
设备部分细分为流式细胞仪、基于影像的细胞计数器和电电阻计数器。 2022 年,流式细胞仪细分市场在市场中获得了显着的收益占有率。这些仪器提供细胞的高通量和多参数分析,使研究人员、临床医生和製药公司能够更深入地了解细胞功能、疾病机制和治疗开发。技术的进步、应用的扩展以及对精确和全面的细胞分析的需求不断增长,导致对流式细胞仪的需求不断增长。
应用前景
依应用划分,市场分为血液分析、干细胞研究、细胞株开发等。 2022 年,血液分析领域在市场中获得了显着的收益占有率。血液分析是临床诊断的基础。由于对准确及时诊断的需求、技术进步、对个人化医疗的关注,以及血液检测在各种医疗保健环境、疾病管理、治疗中的重要作用,推动了血液分析的需求不断增长,已成为研究的基石。 。
最终用途展望
根据最终用途,市场分为製药和生物技术公司、医院和诊断实验室、研究和学术机构等。製药与生技公司细分市场 2022 年的收益占有率最高。一些製药和生物技术公司在市场上发挥重要作用,要么作为自动细胞计数设备的製造商,要么作为该技术用于研究、药物开发和製造过程的用户。
区域展望
从区域来看,我们对北美、欧洲、亚太地区和拉丁美洲地区的市场进行了分析。 2022年,北美地区将占据市场最大的收益占有率份额。北美在市场上占有重要地位。硅谷、波士顿和旧金山等丛集是许多生物技术公司和研究机构的所在地,这些公司和研究机构正在推动自动细胞计数技术的进步。政府对生命科学、生物技术和医疗保健研发的大力资助支持了细胞计数技术的进步。
The Global Automated Cell Counting Market size is expected to reach $8.6 billion by 2030, rising at a market growth of 12.2% CAGR during the forecast period.
Image-based cell counters offer high accuracy and precision in cell counting and analysis. Therefore, the Image-based Cell Counters segment captured $424.4 million revenue in the market in 2022. These systems use advanced imaging technology and algorithms to capture and analyze cell images, providing detailed information about cell morphology, viability, and concentration. As research methodologies become more advanced and diverse, the demand for accurate and efficient cell counting solutions, particularly those based on imaging technology, is expected to grow.
The major strategies followed by the market participants are Product Launches as the key developmental strategy to keep pace with the changing demands of end users. For instance, In September, 2022, Thermo Fisher Scientific, Inc. released the DynaSpin Single-Use Centrifuge system. The system is specifically meant for large-scale cell culture harvesting and aids the users in reducing overall production. Additionally, In October, 2021, Sysmex Corporation unveiled XN-30 Automated Haematology Analyzer for malaria detection. The XN-30 leverages a combination of specialized reagents, advanced algorithms, and violet laser to differentiate P. falciparum from non-falciparum species and find out the life cycle staging of the parasites detected.
Based on the Analysis presented in the KBV Cardinal matrix; F. Hoffmann-La Roche Ltd. are the forerunners in the market. In December, 2021, F. Hoffmann-La Roche Ltd announced the launch of three new automated digital pathology algorithms, uPath Ki-67 (30-9), uPath PR (1E2), and uPath ER (SP1) image analysis for breast cancer. The algorithms facilitate the whole slide analysis workflow with automated pre-computing of the slide image before pathologist assessment which aids the pathologists in quantification of the breast cancer markers. Companies such as Thermo Fisher Scientific, Inc., Abbott Laboratories and Danaher Corporation are some of the key innovators in the market.
COVID-19 Impact Analysis
During the pandemic, research efforts and resources were significantly redirected toward understanding the SARS-CoV-2 virus, developing diagnostic tests, and developing vaccines. This temporary shift in research priorities led to a slowdown in some regions of non-COVID-related research, including automated cell counting applications in other fields. The pandemic disrupted global supply chains, affecting the production, distribution, and availability of mechanical cell counting instruments and related consumables. Delays in manufacturing, shipping constraints, and logistical challenges temporarily impacted the market's growth. Therefore, the COVID-19 pandemic moderately impacted the market.
Market Growth Factors
Growing government expenditure for R&D
Increasing government funding for cell-based research is crucial in advancing scientific discoveries, technological innovations, and therapeutic developments in cell biology, regenerative medicine, and related areas. Increased funding allows scientists to delve deeper into understanding cellular mechanisms, signalling pathways, and the behaviour of various cell types. This fundamental knowledge forms the basis for developing targeted therapies and interventions for chronic diseases. Funding aids in exploring the potential of stem cells in regenerative medicine, tissue engineering, and disease modelling, paving the way for novel treatments and organ regeneration. Thus, the increasing government funding in research and development is driving the growth of the market.
Rising demand for cell-based food products
The growing domain of cellular agriculture, which encompasses the production of cell-based livestock, dairy, eggs, and other products, presents novel applications for automated cell counting instruments. Cell proliferation and culture constitute an integral component of the manufacturing process that necessitates meticulous oversight. Value can be captured in this niche by firms that develop good manufacturing practice (GMP) compliant automated counter solutions for food biomanufacturing facilities. Investments and partnerships with cellular agriculture firms may present opportunities for long-term expansion. Thus, the increasing trend of cell-based food is propelling the growth of the market.
Market Restraining Factors
Requirement for specialized operators and training
Proficient staff and technical knowledge are necessary to operate and maintain sophisticated automated cell counters effectively, particularly those that rely on images. Numerous laboratories hindered by budgetary and resource constraints must provide specialized training. The insufficiency of competent personnel capable of harnessing the complete potential of the systems constitutes a constraining element. Insufficient capacity in healthcare education programs, such as nursing schools and medical colleges, limits the number of qualified professionals entering the field. Hence, a scarcity of trained and skilful personnel is impeding the growth of the market.
Product Outlook
Based on product, the market is bifurcated into instruments and consumables & accessories. The consumables and accessories segment garnered the highest revenue share in the market in 2022. As the adoption of automated cell counting instruments like flow cytometers, image-based cell counters, and haematology analysers rises, so does the need for consumables and accessories associated with these instruments. The increasing demand for consumables and accessories in the market is closely linked to the expanding applications of cell analysis technologies and the need for standardization and quality control.
Instruments Outlook
The instruments segment is subdivided into flow cytometers, image-based cell counters, and electrical impedance coulter counters. In 2022, the flow cytometers segment procured a noteworthy revenue share in the market. These instruments provide high throughput and multiparametric analysis of cells, enabling researchers, clinicians, and pharmaceutical companies to gain deeper insights into cellular functions, disease mechanisms, and therapeutic developments. Technological advancements, expanding applications, and the increasing need for precise and comprehensive cell analysis contribute to the rising demand for flow cytometers.
Application Outlook
On the basis of application, the market is segmented into blood analysis, stem cell research, cell line development, and others. In 2022, the blood analysis segment attained a noteworthy revenue share in the market. Blood analysis is a fundamental aspect of clinical diagnostics. The increasing demand for blood analysis is driven by the need for accurate and timely diagnosis, technological advancements, a focus on personalized medicine, and the crucial role of blood testing in various healthcare settings, making it a cornerstone in disease management, treatment, and research.
End-Use Outlook
Based on the end-use, the market is categorized into pharmaceutical & biotechnology companies, hospitals & diagnostic laboratories, research & academic institutes, and others. The pharmaceutical & biotechnology companies segment witnessed the highest revenue share in the market in 2022. Several pharmaceutical and biotechnological companies play significant roles in the market, either as manufacturers of automated cell counting instruments or as users leveraging this technology for their research, drug development, and manufacturing processes.
Regional Outlook
Region-wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. The North America region witnessed the maximum revenue share in the market in 2022. North America holds a significant position in the market. Regions like Silicon Valley and clusters in Boston and San Francisco are home to numerous biotech firms and research institutions driving technological advancements in automated cell counting. Robust government funding for research and development in life sciences, biotechnology, and healthcare supports advancements in cell counting technology.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Shanghai Ruiyu Biotechnology Co., Ltd. (Alit Biotech (Shanghai) Co., Ltd.), Thermo Fisher Scientific, Inc., Bio-Rad laboratories, Inc., F. Hoffmann-La Roche Ltd., Danaher Corporation, Olympus Corporation, Merck KGaA, Abbott Laboratories, Sysmex Corporation, and Agilent Technologies, Inc.
Recent Strategies Deployed in Automated Cell Counting Market
Product Launches and Product Expansions:
Sep-2022: Thermo Fisher Scientific, Inc. released the DynaSpin Single-Use Centrifuge system. The system is specifically meant for large-scale cell culture harvesting and aids the users in reducing overall production.
Dec-2021: F. Hoffmann-La Roche Ltd announced the launch of three new automated digital pathology algorithms, uPath Ki-67 (30-9), uPath PR (1E2), and uPath ER (SP1) image analysis for breast cancer. The algorithms facilitate the whole slide analysis workflow with automated pre-computing of the slide image before pathologist assessment which aids the pathologists in quantification of the breast cancer markers.
Oct-2021: Sysmex Corporation unveiled XN-30 Automated Hematology Analyzer for malaria detection. The XN-30 leverages a combination of specialized reagents, advanced algorithms, and violet laser to differentiate P. falciparum from non-falciparum species and find out the life cycle staging of the parasites detected.
Sep-2021: Merck KGaA introduced ProCellics Raman Analyzer, a cell culture analyzer. The system uses Bio4C PAT Raman software and delivers in-line and real-time cell culture monitoring.
Dec-2020: Merck KGaA announced the launch of the Scepter 3.0 handheld automated cell counter. The device delivers error-free cell counting by using a combination of analog and digital hardware for sensing, signal processing, data storage, and graphical display. Additionally, it contains a laser-drilled aperture in its cell-sensing zone.
Jan-2020: Olympus Corporation released the Provi CM20 monitoring system, a cell culture monitoring system. The system scans the cultures, and the number of cells and determines confluency on a periodical basis.
Partnerships, Collaborations & Agreements:
Oct-2023: F. Hoffmann-La Roche Ltd signed a partnership with Ibex Medical Analytics, an Israeli biotechnology company, to integrate its Navify Digital Pathology software platform with Ibex's AI-powered decision support tools. Through the partnership, Navify Digital Pathology platform pathologists would be able to securely access third-party AI-powered technology alongside Roche's growing menu of AI-based image analysis tools in an efficient clinical workflow.
Jun-2023: OGT, a subsidiary of Sysmex Corporation, announced a partnership with Applied Spectral Imaging (ASI), an advanced biomedical imaging solutions provider. Under the partnership, OGT would gain the marketing rights for ASI's proprietary cytogenetic imaging and analysis solutions. The partnership would enable clinical laboratories to strengthen their comprehensive genomic structural measurement capabilities.
Feb-2023: Thermo Fisher Scientific, Inc. came into partnership with Celltrio, a Cell Culture automation solutions provider, to develop a fully automated cell culture system for biotherapeutic applications. The solutions that would be developed in the course of the partnership would facilitate the users to deliver innovative therapies to patients by leveraging effective scale processing.
Aug-2020: Thermo Fisher Scientific, Inc. entered a partnership with FCS Express, a flow cytometry software offered by De Novo Software, to integrate its FCS Express software capability with its Invitrogen Attune NxT acoustic flow cytometer system. The combination of the two products would allow the customers to easily compare results across samples and produce publication-quality graphics at the time of instrument installation.
Mergers & Acquisition:
Feb-2021: Thermo Fisher Scientific, Inc. took over cell sorting technology assets from Propel Labs, a cell sorting solutions provider. The acquisition complements and strengthens Thermo Fisher's flow cytometry offering.
Trials and Approvals:
Aug-2023: Abbott Laboratories received approval from the US FDA for its Alinity h-series hematology system. The approval allows Abbott to strengthen its diagnostics business.
Market Segments covered in the Report:
By Product
By Application
By End-use
By Geography
Companies Profiled
Unique Offerings from KBV Research